Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature

Bibliography

• Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-85
   PubMed Web of Science ®Google Scholar
• Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110:1713-22
   PubMed Web of Science ®Google Scholar
• Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/sezary syndrome. Eur J Cancer 2006;42:1014-30
   PubMed Web of Science ®Google Scholar
• Whittaker SJ, Marsden JR, Spittle M, Russell Jones R. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol 2003;149:1095-107
   PubMed Web of Science ®Google Scholar
• Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and sezary syndrome. Blood 2009;114:4337-53
   PubMed Web of Science ®Google Scholar
• Qu L, Tang X. Bexarotene: a promising anticancer agent. Cancer Chemother Pharmacol 2010;65:201-5
   Google Scholar
• Budgin JB, Richardson SK, Newton SB, et al. Biological effects of bexarotene in cutaneous T-cell lymphoma. Arch Dermatol 2005;141:315-21
   PubMed Web of Science ®Google Scholar
• Darro F, Cahen P, Vianna A, et al. Growth inhibition of human in vitro and mouse in vitro and in vivo mammary tumor models by retinoids in comparison with tamoxifen and the RU-486 anti-progestagen. Breast Cancer Res Treat 1998;51:39-55
   Google Scholar
• Song JI, Lango MN, Hwang JD, et al. Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines. Cancer Res 2001;61:5919-25
   PubMed Web of Science ®Google Scholar
• Alyaqoub FS, Liu Y, Tao L, et al. Modulation by bexarotene of mRNA expression of genes in mouse lung tumors. Mol Carcinog 2008;47:165-71
   Google Scholar
• Zhang C, Hazarika P, Ni X, et al. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002;8:1234-40
   PubMed Web of Science ®Google Scholar
• Cesario RM, Stone J, Yen WC, et al. Differentiation and growth inhibition mediated via the RXR:PPARgamma heterodimer in colon cancer. Cancer Lett 2006;240:225-33
   PubMed Web of Science ®Google Scholar
• Yen WC, Prudente RY, Corpuz MR, et al. A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. Br J Cancer 2006;94:654-60
   PubMed Web of Science ®Google Scholar
• Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001;137:581-93
   PubMed Web of Science ®Google Scholar
• Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001;19:2456-71
   PubMed Web of Science ®Google Scholar
• Talpur R, Ward S, Apisarnthanarax N, et al. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2002;47:672-84
   PubMed Web of Science ®Google Scholar
• Abbott RA, Whittaker SJ, Morris SL, et al. Bexarotene therapy for mycosis fungoides and Sezary syndrome. Br J Dermatol 2009;160:1299-307
   PubMed Web of Science ®Google Scholar
• Vakeva L, Ranki A, Hahtola S. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland. Acta Derm Venereol 2012;92:258-63
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ, Morris S, Azurdia R, et al. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol 2013;168:192-200
   PubMed Web of Science ®Google Scholar
• Assaf C, Bagot M, Dummer R, et al. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol 2006;155:261-6
   PubMed Web of Science ®Google Scholar
• Sherman SI, Gopal J, Haugen BR, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 1999;340:1075-9
   PubMed Web of Science ®Google Scholar
• Krejsgaard T, Odum N, Geisler C, et al. Regulatory T cells and immunodeficiency in mycosis fungoides and Sezary syndrome. Leukemia 2012;26:424-32
   PubMed Web of Science ®Google Scholar
• Axelrod PI, Lorber B, Vonderheid EC. Infections complicating mycosis fungoides and Sezary syndrome. Jama 1992;267:1354-8
   PubMed Web of Science ®Google Scholar
• Yarali N, Tavil B, Kara A, et al. Acute renal failure during ATRA treatment. Pediatr Hematol Oncol 2008;25:115-18
   PubMed Web of Science ®Google Scholar
• Whittaker S, Ortiz P, Dummer R, et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056). Br J Dermatol 2012;167:678-87
   PubMed Web of Science ®Google Scholar
• Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2011;29:2598-607
   PubMed Web of Science ®Google Scholar